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Abstract 
Over the last two decades, opioid prescription and prevalence has increased to account 
for over 33,000 deaths per year (Soelberg, Brown, Du Vivier, Meyer & Ramachandran, 2017). 
This is not only due to overdose, but misuse, abuse, and addiction. The abrupt increase in 
prescriptions, pills dispensed, and opioid-related deaths have encouraged the involvement of 
multiple entities. In 2016, the opioid crisis gained the attention of communities that released 
guidelines to regulate prescription of opioid pain management. Such entities include the Center 
for Disease Control and Prevention (CDC), National Institute on Drug Abuse, Agency for 
Healthcare Research and Quality (AHRQ), Arizona Department of Health Services (AZDHS), 
and Substance Abuse and Mental Health Services Administration (SAMHSA). Evidence shows 
that prescribing practices between providers vary. It also shows that providers lack knowledge of 
appropriate opioid prescribing and management. To address this problem, provider education on 
an opioid policy is the most effective way to uniform opioid prescribing.  
Keywords: opioid management, opioid prescribing, prescribing providers, opioid policy 
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Opioid Management: Provider Education 
Opioid abuse, misuse, addiction and overdose have been gradually rising since the 1990’s 
until 2015 when drug overdose was the leading cause of accidental death in the United States 
(ASAM, 2016). This number comes not only from the misuse, but the inappropriate prescribing 
of opioids from providers that lack the knowledge and comfort in these medications. This allows 
for over prescription of opioids, improper disposal, and incomplete follow up from the provider. 
The AZDHS addressed all these inconsistences by administering a new policy outlining 
prescribing guidelines (2018). Therefore, adherence to a clinic-specific policy, following the 
AZDHS guidelines, will increase provider comfort and knowledge in prescribing opioids thereby 
reducing the number of inappropriate prescriptions. 
Background 
The opioid crisis has been addressed multiple times in recent years. In October of 2017, 
The Federal Response to the Opioid Crisis discussed two problems leading to the opioid crisis; 
the rise in opioid analgesic prescriptions since the 1990’s, and the lack of healthcare providers 
that are properly educated by evidence and trained to engage patients in a medication-assisted 
treatment (MAT) to the full capacity. For example, SAMHSA and the CDC have programs that 
center around educating the public and providers on the opioid crisis and necessity for opioid 
management. SAMHSA requires specialized training or board certification from Addiction 
Medicine or Addiction Psychiatry before prescribing buprenorphine, which has been shown to be 
an effective long-term treatment option for opioid dependence (“The prescription opioid,” 2011). 
The CDC provides resources and training on opioid prescriptions through two programs; 
Prescription Drug Overdose: Prevention for States and Data-Driven Prevention Initiative (DDPI) 
and Prescription Drug Monitoring Programs (PDMP) (2018). These include education on 
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insurance practices for opioid prescribing, policies, and laws, such as naloxone administration, 
and Good Samaritan laws.  
SAMHSA currently funds states with $11 million to train providers on opioid overdose 
(“The Federal response,” 2017). The “Opioid Overdose Prevention Toolkit” was released in 
2013 and can be used by people of the community and family members, along with trained 
professionals. It focuses on five steps which are: call for help, checks for signs of opioid 
overdose, support the person’s breathing, administer naloxone, and monitor the person’s 
response (“Opioid overdose prevention”, 2016). More recently, $46 million in grants were 
awarded to help fund 22 states in training individuals that work with communities at high risk for 
opioid overdose. 
The CDC emphasizes the importance of distinguishing the difference between acute and 
chronic pain, and pain that can be treated with opioids verses pain that can be treated with other 
pain management strategies (“Guideline for prescribing,” 2017). Prescribing non-
pharmacological pain management options should be the first treatment approach. This may 
include physical therapy, massage, or acupuncture. Next, medication treatment consists of non-
steroid anti-inflammatories and steroid injections. Obtainable pain management goals should be 
mutually established by the patient and provider. The CDC recommends using immediate-release 
opioids first- beginning with a low dose and going slow with increasing the dose as needed 
(“CDC guideline,” 2016). This recommended protocol should be discussed with the patient when 
the pain management goals are set. If indicated for acute pain, opioids should be restricted to 3-5 
days with a limited quantity. Follow-up is then recommended to reassess pain management 
needs. An informed consent, instead of a pain contract is recommended to all patients that are 
being prescribed an opioid analgesic (“AZ opioid prescribing guidelines”, 2018). The informed 
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consent should discuss the side effects, risk factors for opioid addiction, other medication 
contraindications and dose escalation for opioid prescribing. Providers and patients should 
discuss chronic pain management options beyond the 5-day prescription limit (“CDC guideline,” 
2016). Chronic pain management follow-up is recommended every 3 months, or more if needed. 
At this point, it is recommended the provider and patient discuss the benefits verses risks of 
continuing opioid therapy. The discussion will include the option of combining the therapy with 
other non-opioid pharmacological and non-pharmacological interventions. If it is determined to 
be necessary to increase the opioid dosage, providers should follow the guidelines carefully, 
increasing dosage to >= 50 morphine milligram equivalents (MME) per day and advise avoiding 
increasing dosage to >= 90 MME/day (“CDC guideline,” 2016). 
Prevalence 
The necessity for opioid management has become prevalent because of the rising 
numbers in overdose, use, misuse, and over prescription of opioids. In 2012, 259 million 
prescriptions were written for opioids alone (ASAM, 2016). According to the CDC, there was a 
30% increase in opioid overdoses from July 2016 to September 2017 (“Opioid overdoses 
treated,” 2018). In addition, deaths from opioids have multiplied by five times since 1999. 
Arizona reports 6,369 suspected opioid overdoses with 996 ending in death and 629 cases of 
neonatal abstinence syndrome from June 15, 2017 to March 8, 2018 (“Opioid epidemic,” 2018). 
Over half of these cases were in Maricopa county, followed by Pima County (“Opioid report,” 
2018). Death rates among men are more common than women, but that gap is closing. 
Methadone, Oxycodone and Hydrocodone are the most common drugs associated with overdose 
deaths (“Opioid report,” 2018).  
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Overdose is not the only cause of these numbers. Addiction, misuse, abuse, and over 
prescription contribute to the opioid crisis (“Prescription opioid overdose data”, 2017). Misuse is 
defined as using opioids without a prescription or using prescribed opioids through a different 
route or frequency than was prescribed. It also includes using it for the feeling or experience the 
drugs yield (Hoffman, Lewis, & Nixon, 2017). Because these numbers have grown so rapidly 
over recent years, many statements, policies and guidelines have been published to help 
providers when prescribing opioids for the original purpose of pain management. However, with 
multiple guidelines and recommendations, a single policy for providers at the same practice 
would be the most efficient way to ensure continuity of opioid management. 
PICO 
With the many published guidelines and recommendations on managing controlled 
prescriptions, providers often select the criteria that aligns with personal preferences. This can 
lead to inconsistencies in prescribing and managing opioids among prescribers in practice. At an 
outpatient primary care practice in Southeast Arizona, the 5 physicians and 1 physician assistant 
prescribe opioids based on personal prescribing preferences. There is no single policy or 
procedure in place for management of patients requiring opioid treatment. Each provider 
prescribes opioids using their own discretion. Therefore, several gaps in the process have been 
identified. This makes it difficult to manage patients’ opioid prescriptions and in turn, acute and 
chronic pain. Typically, each provider has the patient sign a pain contract, along with an annual 
urine drug screen. The providers check the prescription drug monitoring program (PDMP) 
anywhere from monthly to yearly. The patients follow up as needed or as the provider sees fit. 
There is no reminder or tracking in the electronic medical record that indicates when the patient 
is due for refills, follow up appointments, urine drug screens. This leads to no reassessment of 
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opioid need and inadequate follow up of opioid pain management. Currently, with no policy or 
guidelines, there is no uniform compliance to opioid management. Therefore, the PICO question 
becomes: in healthcare providers prescribing opioids, how does education on an opioid 
management policy vs not, affect opioid management and policy compliance? 
Search Strategy 
The initial search for this literature review included databases Pubmed, Academic Search 
Premier, GoogleScholar, Lippincott Williams & Wilkins, and Guideline.gov. Keywords that were 
used included; provider education, opioid policy, opioid management and prescribing 
management. The population was focused on providers with an outcome of opioid prescribing 
practices and the effect of opioid management programs. The term opioid prescribing 
management was used in Pubmed which yielded 1262 results (Appendix B, Table B1). This was 
narrowed down by selecting data that occurred in the last five years, while using the terms 
integrated opioid dependence management to narrow the criteria to opioid management 
programs that yielded 52 results (Appendix B, Table B2). 
Google Scholar was searched using palliative care opioid admission which yielded 
18,000 results (Appendix C, Table C1). The search was moved to Academic Search Premier 
using the terms palliative care opioid management under the criteria of being current within the 
last five years that yielded seven results (Appendix C, Table C2). Academic Search Premier was 
searched again using key terms opioid policy with no date restrictions, yielding 216 results 
(Appendix D, Table D1). This was narrowed down using the terms chronic opioid policy and 
restricting articles within the last five years that yielded five results (Appendix D, Table D2). 
Several articles were chosen from the brief abstract and results, but then upon accessing 
the full article that was in Greek and German, they were discarded. Articles were chosen that are 
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in the English language only. After each article was chosen, a review of the references would be 
conducted. These referred to entities such as Pain Medicine, CDC guidelines, National Institute 
on Drug Abuse, and Agency for Healthcare Research and Quality. Articles were then chosen 
based on relevance to address the PICO question.   
Synthesis 
The studies selected ranged from level II to IV evidence due to lack of a control group. 
Of the 10 studies chosen, three studies were cross-sectional with level IV evidence. Two were 
cohort studies of level IV evidence, and three randomized control trials of level I and II evidence. 
Finally, one study was a systematic review of level II evidence and one meta-analysis of level III 
evidence.  
Six of the ten studies addressed screening tools for opioid management interventions such 
as the Opioid Compliance Checklist (OCC) and the Screener and Opioid Assessment for Patients 
with Pain (SOAPP) (Appendix E). Six of the articles addressed interventions for opioid 
management through clinic settings such as the opioid reassessment clinic (ORC) or 
multidisciplinary care (Appendix E). Five of the articles included interventions that had an 
opioid policy, opioid taper, or a tool to reduce inappropriate medications (TRIM) (Appendix E). 
Nine of the studies were conducted in the United States, with one being conducted in several 
clinics across France. Although conducted in two countries, the demographic homogeneity is 
present across all studies as the criteria to be in a study included taking prescribed opioid therapy 
and being over the age of 18 years old.  
Two articles had potential for bias, as the authors were employed by the company 
funding and conducting the study. Besides that, all other studies were funded through 
government health agencies, with the addition of one pharmaceutical company.  Two studies 
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showed attrition rates that were lower than 20% (Appendix E). All tools used across the studies 
reported reliability and validity. 
From these interventions, there was a wide array of dependent variables measured. 
Frequent dependent variables utilized opioid use, patient satisfaction, patient follow-up, provider 
education, and total daily dose (TDD) of oral morphine equivalent (OME). Other variables 
included provider satisfaction, prediction of opioid abuse, medication reconciliation, and if the 
interventions took place in a primary care setting. The studies had a broad range of time from 
three months to two years. Many studies measured outcomes using self-report or self-
questionnaires, along with comparing OME or TDD of opioids. The majority of the findings 
were statistically significant with a p value <.05. If the results were not shown to be statistically 
significant, the quality of evidence and findings were considered for future practice. 
Conclusion About the Evidence 
Multidisciplinary care was the most common intervention across the studies. Primary 
care with a multidisciplinary approach had a consistent increase in patient satisfaction, patient 
follow-up, and decrease in opioid use. Patients in primary care had a greater success in opioid 
abstinence, follow-up and adherence to prescribed opioid therapy, decreasing chances of misuse. 
The two studies that initiated an opioid policy saw decrease in opioid use by mouth. However, 
there was an increase in overall opioid use, namely long acting opioids and opioids used by 
intravenous route (Appendix E). The ORC and opioid taper saw a decrease in opioid use. These 
two studies, along with one of the opioid policies saw a decrease in TDD of OME. Two studies 
addressed the need for provider education in not only prescribing and dosing, but also informing 
patients on proper disposal of opioids.  
Contribution of Theory 
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Bandura’s theory of self-efficacy is applicable to the topic of opioid management and 
education (Bandura, 1977). Opioid management is often inconsistent, especially among primary 
care providers that may be unfamiliar with this territory. Through the theory of self-efficacy, it is 
shown that new information should be taught, demonstrated, then taught back to another person 
such as a patient (Smith, & Liehr, 2014). This would apply when implementing new opioid 
guidelines. This process helps the learner know that the task can be done and reinforces success. 
Bandura’s theory focuses on interventions that change behavior, and in turn, change knowledge 
and clinical practice.  
Evidence Based Practice Model 
The Iowa Model of Evidence- Based Practice to Promote Quality Care is the model to 
use when initiating a new protocol (Melnyk & Fineout-Overholt, 2015). It guides the user 
through the steps to start, research, initiate, and then evaluate a change in practice (Appendix F). 
A primary care clinic has identified a need to establish an opioid use practice guideline to 
comply with the CDC and AZDHS guidelines (2018). A team of 5 family practice Medical 
Doctors (MD) and 1 Physician Assistant (PA) have agreed to participate in this project about 
these new guidelines. A PICO question was formed to search for the best evidence and practice 
for opioid prescribing. Evidenced-based prescribing guidelines, a pain algorithm and an 
informed consent derived from the AZDHS will be provided to the 6 prescribing providers. Ten 
articles were chosen, and then critically appraised to analyze the best evidence, outcomes, and 
practices in initiating an opioid policy. The measurement tool is a self-questionnaire that has 
been adapted from the Arizona Department of Health Services questionnaire. (“Arizona pain and 
addiction curriculum”, 2019). The pre, post and 6-week follow-up questionnaire will include 
questions regarding provider knowledge and comfort in opioid prescribing, procedures in opioid 
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management, and frequency in prescribing, follow up, and referring to other pain management 
options. The next step is obtaining institutional review board approval.  
Brief Potential Plan 
An opioid policy that includes evidenced-based prescribing guidelines, a pain algorithm 
and an informed consent derived from the AZDHS, will be provided to the 6 prescribing 
providers using the CDC and the 2018 AZ Opioid Prescribing Guidelines (2018). This will be 
presented in a PowerPoint presentation and handouts to the stakeholders in the primary care 
practice. The key stakeholders are 5 MDs and 1 PA in the private primary care clinic in 
Southeast Arizona. Additional stakeholders include medical assistants, office managers, and 
receptionists. A pre-questionnaire will be administered to the key stakeholders that measures the 
knowledge of providers in prescribing, management, and beliefs regarding opioids. For example, 
the self-questionnaire will include questions regarding knowledge and comfort in opioid 
prescribing, procedures in opioid management, and frequency in prescribing, follow up, and 
referring to other pain management options.  
The policy guidelines in opioid prescribing and management will be presented through 
PowerPoint presentation and handouts. This will include the AZ Opioid Prescribing guidelines, 
CDC recommendations and other tools that can be utilized to manage opioid prescriptions 
(2018). The same self-questionnaire will be administered after the presentation to measure how 
education on the policy influenced views and practices on prescribing opioids. Another self-
questionnaire will be administered after six weeks to measure the providers prescribing practices 
after education and implementation on the opioid management guidelines. 
Summary with Proposed Implications 
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An opioid policy can streamline management and prescription of opioids. The 
implementation of a policy will condense provider and clinic expectations to one uniform policy 
that can be followed by every member of the clinic, including the patients. Education would 
consist of clearly outlining the prescribing and management practices of the clinic. Education on 
opioid management guidelines, pain algorithm and informed consent reiterates prescribing 
restrictions produced by the CDC and AZDHS(2018). This will reduce the number of 
inappropriate prescriptions and decrease opioid abuse and misuse. 
All providers in the clinic will have one policy to follow, making it efficient to manage 
opioid prescriptions and patients with pain in primary care. Every member of the healthcare team 
would be aware of the new guidelines, therefore taking a multidisciplinary care approach to 
management of opioids. This approach increases patient satisfaction, patient follow up, and 
adherence to opioid management programs.  
Results 
The sample consisted of 2 (33%) females and 4 (66%) males. 1 (17%) of the participants 
was a Physician Assistant and 5 (83%) were Medical Doctors. The average years of clinical 
experience was 24.33 (SD=8.41). 
There were two tests that were used. The Wilcoxon signed rank test was used for the 6 
participants that completed the pre-questionnaire and post-questionnaire. The statistically 
significant result showed a decrease in the question “confidence that opioids are not effective for 
long-term chronic pain”, (p=.034). There was one clinically significant result showing an 
increase in the question “I know community resources to treat patients with pain and/or 
addiction”, (p=.071). The second test that was used measured 3 data collection times; pre-
questionnaire, post-questionnaire and 6-week post-questionnaire. There were 4 participants that 
OPIOID MANAGEMENT  13 
 
 
completed all three questionnaires. There was one statistically significant result that showed an 
increase in the question “I am currently satisfied with my knowledge of managing patients with 
chronic pain”, (p=.039).  
Discussion 
Overall, the results showed an increase in provider knowledge and comfort in treating 
patients with pain. The results showed a decrease in provider confidence that opioids are not 
effective for long-term chronic pain. In other words, after the intervention, the providers had 
increased knowledge that opioids are not effective for long-term chronic pain. The results also 
showed that providers had increased satisfaction with their knowledge of managing patients with 
chronic pain. There also was an increase in providers’ knowing community resources to treat 
patients with pain and addiction. 
 Barriers included the clinic’s resistance to change and lack of time for project 
implementation. The attrition rate of 40% is attributed to lack of provider follow-up. Project 
sustainability is based on the provider and clinic willingness to adopt and continue using the 
prescribing guidelines. Current recommendations based off this project is to implement an opioid 
policy in all primary care clinics to include prescribing guidelines, pain algorithm and an 
informed consent.  
Conclusion 
This project, utilizing the CDC and 2018 AZ Opioid Prescribing Guidelines, created a 
policy that included guidelines, a pain algorithm, and informed consent for the primary care 
providers (“Arizona opioid prescribing guidelines”, 2018). All information was presented via 
PowerPoint and paper handouts. A pre, post and 6-week follow-up questionnaire included 
questions regarding provider knowledge and comfort in opioid prescribing, procedures in opioid 
OPIOID MANAGEMENT  14 
 
 
management, and frequency in prescribing, follow up, and referring to other pain management 
options. The data collected from the pre-questionnaire and post-questionnaires showed that there 
was an increase in provider knowledge and satisfaction when prescribing opioids after the 
intervention. 
In summary, this project made the 2018 AZ Opioid Prescribing Guidelines into a useable, 
manageable set of guidelines that is easily applicable into a primary care practice.  
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Appendix A 
Table A1 
PubMed Database Screenshot 
 
Table A2 
PubMed Database Screenshot
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Appendix B 
Table B1 
GoogleScholar Database Screenshot
 
Table B2 
Academic Search Premier Database Screenshot 
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Appendix C 
Table C1 
Academic Search Premier Database Screenshot 
 
Table C2 
Academic Search Premier Database Screenshot 
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Key: ↓- decrease; ↑- increase; ABC-addiction behavior checklist; AUC- area under curve; BPI- brief pain inventory; CG- control group; DV-dependent variable; 
DX-diagnosis; ED- erectile dysfunction; HADS- hospital anxiety and depression scale;  HX-history; IV- independent variable; LOE- level of evidence; MAT- 
medication-assisted treatment; MEDD- morphine equivalent daily dose; MI- myocardial infarction; N-number of studies; n- number of participants; O-opioid; 
OBGYN- Obstetrician/Gynecologist; OCC-Opioid Compliance Checklist; OD- overdose; OME- oral morphine equivalent; ORC-opioid reassessment clinic; 
OUD- Opioid Use Disorder; PACIC- patient assessment of care for chronic conditions; PCP- primary care provider; PDI- pain disability index; PO- by mouth; 
PT-patient; R- reliability; RX-prescription; SOAPP-R- screener and opioid assessment for pain patients revised; TDD- total daily dose; TRIM- Tool to Reduce 
Inappropriate Medications;    
 
Appendix D 
Table 1 
Evaluation Table: Opioid Management 
 
Citation Theory/ 
Concep
tual 
Frame
work 
Design/ 
Method 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement/ 
Instrumentatio
n 
Data 
Analysi
s 
 
Findings/ 
Results 
Level/Qualit
y of 
Evidence;  
Becker, W., et al. (2017).  
Country: U.S. 
Fund: VA’s Office of Research and 
Development, Health 
Services Research, Substance 
Use Disorder QUERI 
Bias: none 
 
Physiol
ogic 
model 
Cohort 
study  
CG= none 
Purpose: 
To describe 
the 
preliminary 
efficacy of 
the ORC 
n= 87 
CG= none 
mean age- 56.2 
Pt. type- 
84% pts hx of 
substance 
abuse/dependenc
e, 70% pts 
current misuse 
of rx o, 22% new 
substance use 
disorder dx 
Setting-ORC 
IV-
involvemen
t in ORC 
DV- mean 
change in 
MEDD, 
patient 
satisfaction, 
number of 
pt.s 
engaged 
ORC 
treatment 
Medical record 
referral from 
PCP; 
motivational 
interviewing 
Not 
identitif
ed- 
compar
e pre 
and post 
MEDD 
Pt.s pre-
ORC admit 
mean of 
202.8mg 
MEDD, 
post ORC 
169.4mg 
MEDD, pt. 
satisfaction 
3.8/5, 
LOE: IV 
Limitations: 
Not shown 
in 
statistically 
significant, 
no CG 
Citation Theory/ Design/ Sample/ Setting Major Measurement/ Data Findings/ Level/Qualit
OPIOID MANAGEMENT  23 
 
Key: ↓- decrease; ↑- increase; ABC-addiction behavior checklist; AUC- area under curve; BPI- brief pain inventory; CG- control group; DV-dependent variable; 
DX-diagnosis; ED- erectile dysfunction; HADS- hospital anxiety and depression scale;  HX-history; IV- independent variable; LOE- level of evidence; MAT- 
medication-assisted treatment; MEDD- morphine equivalent daily dose; MI- myocardial infarction; N-number of studies; n- number of participants; O-opioid; 
OBGYN- Obstetrician/Gynecologist; OCC-Opioid Compliance Checklist; OD- overdose; OME- oral morphine equivalent; ORC-opioid reassessment clinic; 
OUD- Opioid Use Disorder; PACIC- patient assessment of care for chronic conditions; PCP- primary care provider; PDI- pain disability index; PO- by mouth; 
PT-patient; R- reliability; RX-prescription; SOAPP-R- screener and opioid assessment for pain patients revised; TDD- total daily dose; TRIM- Tool to Reduce 
Inappropriate Medications;    
 
Concep
tual 
Frame
work 
Method Variables & 
Definitions 
Instrumentatio
n 
Analysi
s 
(stats 
used) 
Results y of 
Evidence;  
Carrieri, et al. (2014)  
Country: France 
Fund: French National Agency for 
Research on Aids and Viral 
Hepatitis and French Ministry 
of Health 
Bias: None 
 
Physiol
ogic 
model 
Randomize
d Control 
trial 
Purpose: 
compare 
effectivene
ss of 
methadone 
tx between 
primary 
care and 
specialized 
care 
N= 221 
Primary care, 
specialized care 
Attrition: 17% 
IV- 
supervised 
methadone 
treatment 
for 2 weeks 
DV- 
abstinence 
scoring, pt. 
outcomes, 
provider 
outcomes 
Self-reported 
abstinence 
from street 
opioids, pt. 
retention, 
satisfaction 
Intentio
n to 
treat 
Abstinent: 
55% 
primary 
care, 33% 
specialized 
care, ↑ pt. 
satisfaction 
in primary 
care, pt. 
involvemen
t lower in 
specialized 
care, 
LOE: II 
Better 
outcomes 
with o 
management 
in primary 
care 
Citation 
Concep
tual 
Frame
work 
Design/ 
Method/ 
Sampling 
(Grounded 
Theory, 
phenomeno
logy, 
Narrative
…) 
Sample/Setting 
(describe) 
Major 
Variables 
Studied and 
Their 
Definitions 
Measurement/ 
Instrumentatio
n 
(focus group, 
1:1, 
researcher(s) 
Data 
Analysi
s 
Findings/ 
Themes 
Quality of 
Evidence 
Chou, R., et al. (2014).  
Country: U.S. 
Fund: Agency for Healthcare Research 
and Quality 
Bias: none 
 
Qualita
tive 
Docum
ent 
analysi
s 
Descriptive 
exploratory
; grounded 
theory 
Purpose: 
review 
N=39 studies 
Articles are 
about long-term 
o therapy for 
chronic pain 
Exclusion: 
Risks of O 
vs placebo 
in pt.s with 
chronic 
pain 
 
Systematic 
review via 
questionnaire 
Long 
term o 
use ↑ 
risk of 
abuse/d
ependen
Buccal 
fentanyl or 
intranasal 
fentanyl 
more 
effective 
LOE: II 
No 
difference in 
dose 
escalation 
vs. 
OPIOID MANAGEMENT  24 
 
Key: ↓- decrease; ↑- increase; ABC-addiction behavior checklist; AUC- area under curve; BPI- brief pain inventory; CG- control group; DV-dependent variable; 
DX-diagnosis; ED- erectile dysfunction; HADS- hospital anxiety and depression scale;  HX-history; IV- independent variable; LOE- level of evidence; MAT- 
medication-assisted treatment; MEDD- morphine equivalent daily dose; MI- myocardial infarction; N-number of studies; n- number of participants; O-opioid; 
OBGYN- Obstetrician/Gynecologist; OCC-Opioid Compliance Checklist; OD- overdose; OME- oral morphine equivalent; ORC-opioid reassessment clinic; 
OUD- Opioid Use Disorder; PACIC- patient assessment of care for chronic conditions; PCP- primary care provider; PDI- pain disability index; PO- by mouth; 
PT-patient; R- reliability; RX-prescription; SOAPP-R- screener and opioid assessment for pain patients revised; TDD- total daily dose; TRIM- Tool to Reduce 
Inappropriate Medications;    
 
 current 
evidence 
on the 
effectivene
ss and 
harms of O 
therapy for 
chronic 
pain (>=1 
year) 
conference 
abstracts, non-
english 
language, 
nonhuman 
subjects 
ce, 
↑OD, 
↑fractur
es, ↑MI, 
↑use of 
ED 
medicat
ions or 
testoster
one 
replace
ment,  
than oral O 
in acute 
pain, no 
difference 
in methods 
for o 
discontinua
tion, OCC 
inconsisten
t accuracy, 
SOAPP 6 
sensitivity 
.73, 8 .at 68 
maintenance 
of O on 
pain, 
function, 
risk of 
withdrawal 
due to o 
misuse 
A lot of 
questions- 
insufficient/l
ow evidence 
Citation 
 
 
 
 
  
Theory/ 
Concep
tual 
Frame
work 
Design/ 
Method 
Sample/ Setting Major 
Variables 
& 
Definitions 
Measurement/ 
Instrumentatio
n 
Data 
Analysi
s 
 
Findings/ 
Results 
Level/Qualit
y of 
Evidence 
Fried, T., et al. (2017).  
Country: U.S. 
Fund: Donaghue Foundation and Yale 
University School of Medicine 
Bias: none 
Physiol
ogic  
Randomize
d clinical 
trial 
Purpose: 
determine 
effectivene
ss of the 
web tool, 
TRIM 
linking to 
electronic 
health 
record 
n=64 
CG=64 
veteran, 65 or 
older prescribed 
7 or more 
medications 
random receipt 
of TRIM or 
usual care 
 IV: 
Involvemen
t in TRIM 
DV: 
physician 
outcomes, 
patient 
outcomes 
PACIC 
Changes in 
medications 
Chi-
square, 
Kruskal
-Wallis, 
p<.10 
Statistically 
significant:
↑ PACIC 
>10, ↑ 1+ 
clinician 
recommend
ation, ↑pt. 
active 
participatio
n, ↑pt. and 
clinician 
medication 
communica
tion, ↑ 
clinician 
facilitative 
LOE: II 
Statistically 
significant, 
48.4% errors 
corrected via 
medication 
reconciliatio
n 
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Key: ↓- decrease; ↑- increase; ABC-addiction behavior checklist; AUC- area under curve; BPI- brief pain inventory; CG- control group; DV-dependent variable; 
DX-diagnosis; ED- erectile dysfunction; HADS- hospital anxiety and depression scale;  HX-history; IV- independent variable; LOE- level of evidence; MAT- 
medication-assisted treatment; MEDD- morphine equivalent daily dose; MI- myocardial infarction; N-number of studies; n- number of participants; O-opioid; 
OBGYN- Obstetrician/Gynecologist; OCC-Opioid Compliance Checklist; OD- overdose; OME- oral morphine equivalent; ORC-opioid reassessment clinic; 
OUD- Opioid Use Disorder; PACIC- patient assessment of care for chronic conditions; PCP- primary care provider; PDI- pain disability index; PO- by mouth; 
PT-patient; R- reliability; RX-prescription; SOAPP-R- screener and opioid assessment for pain patients revised; TDD- total daily dose; TRIM- Tool to Reduce 
Inappropriate Medications;    
 
communica
tion,  
Citation Theory/ 
Concep
tual 
Frame
work 
Design/ 
Method 
Sample/ Setting Major 
Variables 
& 
Definitions 
Measurement/ 
Instrumentatio
n 
Data 
Analysi
s 
 
Findings/ 
Results 
Level/Qualit
y of 
Evidence 
Hoffman, L., et al. (2017).  
Country: U.S. 
Fund: National Institute on Drug 
Abuse and National Institute on 
Alcohol Abuse and Alcoholism 
Bias: none 
 
physiol
ogic 
Design: 
Cross-
sectional 
Purpose: 
changes in 
O misuse 
among pt.’s 
with new 
legislative 
response 
n= 396 
two Florida 
based in pt. 
cohorts 
 
 
IV- 
legislative 
response 
DV- pre 
and post 
policy 
opioid use; 
any O, Rx 
O, illicit O; 
PO and 
Intravenous 
 
 
 
Self- report 
questionnaire 
R- not tested 
t-tests 
chi 
square      
analyses 
Fisher’s 
exact 
stats 
post policy 
use:  
any O: 
↑24.21% 
Rx O: 
↑20.96% 
Illicit O: 
↑5.85% 
PO: 
↓37.6% 
Intravenous
: ↑34.43% 
LOE: IV 
No CG 
Increase in 
overall o use 
after policy 
limit; 
namely 
intravenous 
Citation Theory/ 
Concep
tual 
Frame
work 
Design/ 
Method 
Sample/ Setting Major 
Variables 
& 
Definitions 
Measurement/ 
Instrumentatio
n 
Data 
Analysi
s 
 
Findings/ 
Results 
Level/Qualit
y of 
Evidence 
 
Jamison, R., et al. (2016).  
Country: U.S. 
Fund: Mallinckrodt and Pfizer 
Bias: none 
 
physiol
ogic 
Metanalysi
s 
Purpose: 
Assess the 
efficacy of 
the OCC 
for 
managing 
chronic 
n= 177 
CG: (original 
study n=157) 
female: 106 
male: 71 
patients 
prescribed O in 
primary care 
IV- 
questionnai
res 
DV- pt.’s 
self-
reported 
answers 
OCC, BPI, 
PDI (R .91), 
HADS (.83), 
SOAPP-R 
(sensitivity 
.86), ABC, 
urine 
toxicology, 
 
Multiva
riate 
logistic 
regressi
on 
models 
“Run out of 
your pain 
medication 
early”-
AUC .606 
Missed any 
scheduled 
medical 
appointmen
LOE: III 
Questions 5 
&6 best 
identifying o 
misuse at 
baseline 
**Pt.s in 
PCP had 
lower drug 
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Key: ↓- decrease; ↑- increase; ABC-addiction behavior checklist; AUC- area under curve; BPI- brief pain inventory; CG- control group; DV-dependent variable; 
DX-diagnosis; ED- erectile dysfunction; HADS- hospital anxiety and depression scale;  HX-history; IV- independent variable; LOE- level of evidence; MAT- 
medication-assisted treatment; MEDD- morphine equivalent daily dose; MI- myocardial infarction; N-number of studies; n- number of participants; O-opioid; 
OBGYN- Obstetrician/Gynecologist; OCC-Opioid Compliance Checklist; OD- overdose; OME- oral morphine equivalent; ORC-opioid reassessment clinic; 
OUD- Opioid Use Disorder; PACIC- patient assessment of care for chronic conditions; PCP- primary care provider; PDI- pain disability index; PO- by mouth; 
PT-patient; R- reliability; RX-prescription; SOAPP-R- screener and opioid assessment for pain patients revised; TDD- total daily dose; TRIM- Tool to Reduce 
Inappropriate Medications;    
 
 
Citation 
Theory/ 
Concept
ual 
Framew
ork 
Design/ 
Method 
Sample/ Setting Major 
Variables 
& 
Definitions 
Measurement/ 
Instrumentatio
n 
Data 
Analysi
s 
 
Findings/ 
Results 
Level/Qualit
y of 
Evidence 
Lagisetty, P., et al. (2017).  
Country: U.S. 
Fund: None identified 
Bias: none  
physiol
ogic 
Systematic 
review 
Purpose: 
analyze 
current 
primary 
care OUD 
MAT 
program 
interventio
ns and 
processes 
that lead to 
improved 
pt. 
outcomes 
 
 
N= 35 
10 randomized 
control trials, 25 
quasi-
experimental 
interventions in 
primary care in 8 
countries 
IV-
interventio
ns; 
organizatio
n, process, 
environme
nt, person, 
technology 
DV- % of 
studies 
with 
common 
themes 
Evaluation 
tables 
Not 
identifie
d, 
commo
n 
themes 
 
 
 
↑pt. 
retention, 
consistent 
need for 
physician 
education,  
LOE: II 
A lot of 
themes 
running 
throughout, 
overall best 
results with 
multidiscipli
nary care 
Citation Theory/ 
Concept
ual 
Framew
ork 
Design/ 
Method 
Sample/ Setting Major 
Variables 
& 
Definitions 
Measurement/ 
Instrumentatio
n 
Data 
Analysi
s 
 
Findings/ 
Results 
Level/Qualit
y of 
Evidence 
pain 
patients 
using O 
compared 
to an 
original 
study 
ts”- 
AUC.607 
misuse, 
OCC 3x, 
then 
Questions 
1,5,6 
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Key: ↓- decrease; ↑- increase; ABC-addiction behavior checklist; AUC- area under curve; BPI- brief pain inventory; CG- control group; DV-dependent variable; 
DX-diagnosis; ED- erectile dysfunction; HADS- hospital anxiety and depression scale;  HX-history; IV- independent variable; LOE- level of evidence; MAT- 
medication-assisted treatment; MEDD- morphine equivalent daily dose; MI- myocardial infarction; N-number of studies; n- number of participants; O-opioid; 
OBGYN- Obstetrician/Gynecologist; OCC-Opioid Compliance Checklist; OD- overdose; OME- oral morphine equivalent; ORC-opioid reassessment clinic; 
OUD- Opioid Use Disorder; PACIC- patient assessment of care for chronic conditions; PCP- primary care provider; PDI- pain disability index; PO- by mouth; 
PT-patient; R- reliability; RX-prescription; SOAPP-R- screener and opioid assessment for pain patients revised; TDD- total daily dose; TRIM- Tool to Reduce 
Inappropriate Medications;    
 
Madsen, A., et al. (2018).  
Country: U.S. 
Fund: Maternal and Child Health 
Bureau, Health resources and services 
administration, Department of Health 
and Human Services 
Bias: none 
physiol
ogic 
Cross 
sectional 
survey, 
mixed 
methods 
Purpose: 
to discover 
OBGYN’s 
knowledge 
and 
practice for 
rx O 
n= 300 
CG= n/a 
179 responded 
OBGYN fellows 
pat of the 
Collaborative 
Ambulatory 
Research 
Network 
IV- 
questionnai
re- 1. 
Screening 
for 
dependence 
2. Rx the 
smallest 
amount 
required 3. 
Tailoring 
Rx 4. 
Counseling 
on proper 
disposal 
DV- 
providers 
responses 
Survey; tested 
on group of 
volunteer 
physicians- no 
adjustments 
made 
Pearson 
X2, 
Fisher 
exact 
test, t-
test 
Provider 
responses: 
74% rx for 
smallest # 
of pills 
p=.004, 
56% aware 
of proper 
disposal, 
19% know 
misuse 
source 
from friend 
or family 
LOE: IV 
But 
measuremen
t of 
prescriber 
knowledge
…. 
Not 
statistically 
significant, 
but 
important; 
22% O 
dependence 
screening, 
62% tailor O 
Rx, 17% 
counsel on 
proper 
disposal 
Citation Theory/ 
Concept
ual 
Framew
ork 
Design/ 
Method 
Sample/ Setting Major 
Variables 
& 
Definitions 
Measurement/ 
Instrumentatio
n 
Data 
Analysi
s 
 
Findings/ 
Results 
Level/Qualit
y of 
Evidence 
Page, J., et al. (2018).  
Country: U.S. 
Fund: Moda Health 
Bias: Authors were employed by 
Moda Health 
 
physiol
ogic 
Cohort 
Study 
Purpose: 
evaluate 
effect of 
voluntary 
O tapering 
program on 
MEDD 
n=113 
CG= none 
attrition: 7% 
due to no 
provider 
response 
inclusion: 
providers with 
>90 days of 
pharmacy claims 
IV- 
enrollment 
in O 
tapering 
program 
DV- 
MEDD 
Pharmacy 
records; ICD-
10-CM codes 
Doesn’t 
specify; 
compar
e 
MEDD 
before 
and 
after 
program 
over 3 
Change in 
MEDD by 
pt.: 0%, 
↓3.6%, 
↓4.5%, 
↓42.9%, 
↓45.5%, 
↓46.1% 
No 
program 
LOE: IV 
Restrictions
: 6 in 
program, 
study 
measured 
MEDD for 
all 113 
participants 
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Key: ↓- decrease; ↑- increase; ABC-addiction behavior checklist; AUC- area under curve; BPI- brief pain inventory; CG- control group; DV-dependent variable; 
DX-diagnosis; ED- erectile dysfunction; HADS- hospital anxiety and depression scale;  HX-history; IV- independent variable; LOE- level of evidence; MAT- 
medication-assisted treatment; MEDD- morphine equivalent daily dose; MI- myocardial infarction; N-number of studies; n- number of participants; O-opioid; 
OBGYN- Obstetrician/Gynecologist; OCC-Opioid Compliance Checklist; OD- overdose; OME- oral morphine equivalent; ORC-opioid reassessment clinic; 
OUD- Opioid Use Disorder; PACIC- patient assessment of care for chronic conditions; PCP- primary care provider; PDI- pain disability index; PO- by mouth; 
PT-patient; R- reliability; RX-prescription; SOAPP-R- screener and opioid assessment for pain patients revised; TDD- total daily dose; TRIM- Tool to Reduce 
Inappropriate Medications;    
 
with MEDD >0 months change in 
MEDD: 
↓ in 10.3%, 
0% in 
20.6%, ↑ in 
67.3% 
Citation Theory/ 
Concept
ual 
Framew
ork 
Design/ 
Method 
Sample/ Setting Major 
Variables 
& 
Definitions 
Measurement/ 
Instrumentatio
n 
Data 
Analysi
s 
 
Findings/ 
Results 
Level/Qualit
y of 
Evidence 
Riggs, C., et al. (2017). 
Country: U.S. 
Fund: Department of Pharmacy at 
Kaiser Permanente Colorado 
Bias: authors employed by Kaiser 
Permanente Colorado 
physiol
ogic 
Cross-
sectional 
Purpose: 
compare 
average 
total daily 
dose of O 
purchased 
by Kaiser 
Permanente 
Colorado 
Medicaid 
pt.s before 
and after 
Medicaid 
short-
acting O 
quantity 
limit 
n= 2, 
449 pts 
CG= none 
Age- 45.2 
 
Kaiser 
Permanente 
Colorado 
Medicaid pt.s 
Inclusion: pt. to 
purchase at least 
1 short-acting O 
using Medicaid 
at KP pharmacy 
IV- 
Medicaid O 
quantity 
limit 
DV- # of O 
purchased 
before and 
after 
quantity 
limit  
Electronic 
medical and 
pharmacy 
records to 
assess 
medication use 
Wilcox
on’s 
two 
sample 
test and 
signed-
rank 
test, chi 
square 
tests, 
McNem
ar’s test 
Postperiod 
TDD 
OME: ↓ 
10mg, p 
<.0001 
Long-
acting o: 
↑3.5% 
P=.060, 
Any 
adjuvant 
nonopioid: 
↓10.9%, p= 
<.001 
   
LOE: IV 
No CG 
Statistically 
significant ↓ 
in nonopioid 
rx and TDD 
OME,  
↑ in long 
acting 
opiods, 
pvalue not 
significant  
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KEY: ↓ - Decreased, ↑ - Increased, CH- Cohort study, CS- cross-sectional study, I- insufficient evidence, LOE- 
level of evidence, MA- meta-analysis, MDC- multidisciplinary care, MM- mixed methods study, O- opioid, 
OCC- opioid compliance checklist, OME- oral morphine equivalent, ORC- opioid reassessment clinic, OT- 
observational trials, Pt.- Patient, Pr- provider, QE- quasi experimental, RCT- randomized control trial, S- 
satisfaction, SOAPP- screener and opioid assessment for patients with pain, SR- systematic review, TDD- total 
daily dose, TRIM- Tool to Reduce Inappropriate Medications 
 
Appendix E 
Table E1 
Synthesis Table: Opioid management 
 
 
Studies 
Be
ck
er
, W
., 
et
 a
l. 
C
ar
ri
er
i, 
et
 a
l. 
C
ho
u,
 R
., 
et
 a
l. 
Fr
ie
d,
 T
., 
et
 a
l. 
H
of
fm
an
, L
., 
et
 
al
. 
Ja
m
iso
n,
 R
., 
et
 
al
.  
 
La
gi
se
tty
, P
, e
t 
al
. 
M
ad
se
n,
 A
., 
et
 
al
. 
Pa
ge
, J
., 
et
 a
l. 
  
R
ig
gs
, C
., 
et
 a
l. 
Ba
sic
s 
 
Year   
2017 
 
2014 
    
2014 
   
2017 
       
2017 
 
2016 
  
2017 
  
2018 
  
2018 
  
2017 
LOE        
IV 
      
II 
 
II 
  
II 
  
IV 
  
III 
          
I 
  
IV 
  
IV 
 
IV 
Design CH RCT SR RCT CS MA RCT, 
QE, 
OT 
CS, 
MM  
CH CS 
           
Mean 
Age 
56.2         45.2 
Attrition   
17% 
        
7% 
 
Bias           X 
# of 
participa
nts 
         
87 
       
221 
   
39 
      
128   
 
396 
    
177 
         
35 
        
179 
 
113 
 
2449 
In
te
rv
en
tio
ns
 
policy     X     X 
O taper   X      X  
OCC   X   X  X   
SOAPP   X   X     
ORC X          
TRIM    X       
MDC X X  X  X X    
           
  
M
aj
or
 
Fi
nd
in
gs
 
      
 
            
O use ↓ ↓ I  ↑IV, ↓ 
PO, 
↑overall  
   ↓ ↓, ↑long 
acting 
opioids 
Pr. S       I    
Pt. S ↑, 
3.8/5 
↑ ↑ ↑       
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KEY: ↓ - Decreased, ↑ - Increased, CH- Cohort study, CS- cross-sectional study, I- insufficient evidence, LOE- 
level of evidence, MA- meta-analysis, MDC- multidisciplinary care, MM- mixed methods study, O- opioid, 
OCC- opioid compliance checklist, OME- oral morphine equivalent, ORC- opioid reassessment clinic, OT- 
observational trials, Pt.- Patient, Pr- provider, QE- quasi experimental, RCT- randomized control trial, S- 
satisfaction, SOAPP- screener and opioid assessment for patients with pain, SR- systematic review, TDD- total 
daily dose, TRIM- Tool to Reduce Inappropriate Medications 
 
 
 
 
 
 
  
 
 
 
 
need for 
provider 
education 
      X X   
Predictio
n of 
abuse 
  I   X     
TDD 
OME 
↓        ↓ ↓ 
Med. 
Rec. 
  ↑ X       
Pt. 
followup 
 ↑  ↑   ↑    
Primary 
care 
 X    X X    
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Appendix F 
Iowa model of EBP 
 
